Domenico Magazzù - Concepedia

Author

Domenico Magazzù

Also Known As

D Magazzu', D. Magazzu, D. Magazzu’, D. Magazzù, Domenico Magazzu, Domenico Magazzu', Domenico Magazzù, Domenico Magazzù

Publications

Citations

H-Index

Concepts

All Affiliations

Fondazione Michelangelo Fondazione IRCCS Istituto Nazionale dei Tumori University of Pavia INCLIVA Health Research Institute Hospital Clínico Universitario de Valencia

About

Domenico Magazzù is an author at Fondazione Michelangelo specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.6K
2	Immunology	5	5	1K
3	Health Sciences	3	3	524
4	Cell Biology	1	1	16
5	Diabetes	1	1	27

Domenico Magazzù

Publications

Citations

H-Index

Page 1

	Year	Citations
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, The Lancet Oncology 5-Year AnalysisBreast OncologyMedicineRandomised TrialImmunology	2016	846
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Luca Gianni, W. Eiermann, Aňa Lluch, The Lancet Oncology Breast OncologyOncologySuperiority TrialClinical TrialsBreast Cancer	2014	487
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial Luca Gianni, Mauro Mansutti, Antonio Antón, JAMA Oncology	2018	153
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients Giovanni Squadrito, Teresa Pollicino, Irene Cacciola, Cancer	2006	134
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial Giampaolo Bianchini, Lajos Pusztai, Tadeusz Pieńkowski, Annals of Oncology Neosphere TrialCancer ImmunosurveillancePathologic Complete ResponseMedicineImmunology	2015	133
Are car drivers holding a motorcycle licence less responsible for motorcycle—Car crash occurrence? Domenico Magazzù, Mario Comelli, Alessandra Marinoni Accident Analysis & Prevention Motorcycle—car Crash OccurrenceDriver BehaviorRoad Traffic SafetyMotorcycle LicenceTransport Accident	2005	106
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure Andrea Necchi, Andrea Anichini, Daniele Raggi, Clinical Genitourinary Cancer Lymphoid NeoplasiaOncologyMedicineImmunologyPathology	2016	29
Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study Giuseppina Russo, A. Di Benedetto, Domenico Magazzù, Acta Diabetologica Metabolic SyndromeGenetic DeterminantMetabolic DisorderGeneticsDiabetes	2009	27
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. Luca Gianni, W. Eiermann, Alexey Manikhas, Journal of Clinical Oncology Breast OncologyMonoclonal Antibody TrastuzumabImmunologyPathologyFollow-up Results	2013	20
An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01). Andrea Necchi, Domenico Magazzù, Andrea Anichini, Journal of Clinical Oncology Oncologic ImagingPathologyImmunotherapeuticsImmune ProfilingOncology	2016	17

Page 1